Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer

R. Hubbard; F. Peintinger; C. Liedtke; C. Hatzis; H. M. Kuerer; V. Valero; A. U. Buzdar; G. N. Hortobagyi; L. Pusztai; W. F. Symmans

doi:10.1200/jco.2008.26.15_suppl.544

Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.544 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 544-544

Author(s):

R. Hubbard ◽

F. Peintinger ◽

C. Liedtke ◽

C. Hatzis ◽

H. M. Kuerer ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Value ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Anthracycline Chemotherapy

Download Full-text

Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

PLoS ONE ◽

10.1371/journal.pone.0234191 ◽

2020 ◽

Vol 15 (6) ◽

pp. e0234191 ◽

Cited By ~ 3

Author(s):

Anne-Sophie Hamy ◽

Lauren Darrigues ◽

Enora Laas ◽

Diane De Croze ◽

Lucian Topciu ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Prognostic Value ◽

Breast Cancer Subtype ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Cancer Subtype

Download Full-text

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-0560 ◽

2019 ◽

Vol 25 (16) ◽

pp. 4985-4992 ◽

Cited By ~ 2

Author(s):

Tessa G. Steenbruggen ◽

Maartje van Seijen ◽

Liselore M. Janssen ◽

Mette S. van Ramshorst ◽

Erik van Werkhoven ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Prognostic Value ◽

Residual Disease ◽

Her2 Positive ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Response Index ◽

Positive Breast Cancer

Download Full-text

Primary systemic chemotherapy in stage II-IIIb breast cancer: Independent prognostic value of molecular phenotype and the MDACC residual cancer burden—A single-institutional experience.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e21132 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e21132-e21132

Author(s):

E. M. Aguirre Ortega ◽

M. Taberner Bonastre ◽

S. Morales Murillo ◽

E. Iglesias Martinez ◽

C. Canosa Morales ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Value ◽

Systemic Chemotherapy ◽

Stage Ii ◽

Molecular Phenotype ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Primary Systemic Chemotherapy ◽

Institutional Experience

Download Full-text

Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer

Gland Surgery ◽

10.21037/gs-21-608 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Wei Wang ◽

Yinhua Liu ◽

Hong Zhang ◽

Shuang Zhang ◽

Xuening Duan ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Prognostic Value ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden

Download Full-text

Abstract P2-07-04: Prognostic value of residual cancer burden (RCB), neo-bioscore and neoadjuvant response index (NRI) to evaluate response to neoadjuvant trastuzumab-based therapy in HER2-positive breast cancer (BC)

10.1158/1538-7445.sabcs18-p2-07-04 ◽

2019 ◽

Author(s):

TG Steenbruggen ◽

M van Seijen ◽

LM Janssen ◽

MS van Ramshorst ◽

E van Werkhoven ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Value ◽

Her2 Positive ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Response Index ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4303-8 ◽

2017 ◽

Vol 165 (1) ◽

pp. 181-191 ◽

Cited By ~ 21

Author(s):

Jeffrey I. Campbell ◽

Christina Yau ◽

Polina Krass ◽

Dan Moore ◽

Lisa A. Carey ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Pathologic Complete Response ◽

Complete Response ◽

Cancer Staging ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

American Joint Committee

Download Full-text

Histological Evaluation of Therapeutic Effect and RCB (Residual Cancer Burden) Index in Primary Breast Cancer Operated after Neoadjuvant Chemotherapy: Retrospective Study of the Clinicopathological Findings and Prognosis

The Showa University Journal of Medical Sciences ◽

10.15369/sujms.29.181 ◽

2017 ◽

Vol 29 (2) ◽

pp. 181-192

Author(s):

Seiya HAJIKANO ◽

Yuko HIROTA ◽

Nobukazu SHIMA ◽

Reika SUZUKI ◽

Terumasa SAWADA ◽

...

Keyword(s):

Breast Cancer ◽

Retrospective Study ◽

Neoadjuvant Chemotherapy ◽

Therapeutic Effect ◽

Primary Breast Cancer ◽

Histological Evaluation ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Clinicopathological Findings

Download Full-text

Abstract P2-16-09: Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS)

10.1158/1538-7445.sabcs19-p2-16-09 ◽

2020 ◽

Cited By ~ 1

Author(s):

Haven Garber ◽

Gaiane Rauch ◽

Beatriz Adrada ◽

Rosalind Candelaria ◽

Elizabeth Mittendorf ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Ongoing Clinical Trial ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden

Download Full-text

Abstract P6-02-02: Near-infrared spectral tomography (NIRST): A prognostic assessment tool for predicting residual cancer burden (RCB) during neoadjuvant chemotherapy (NAC) in breast cancer (BC)

10.1158/1538-7445.sabcs18-p6-02-02 ◽

2019 ◽

Author(s):

B Batukbhai ◽

S Jiang ◽

EB Bernhardt ◽

K Muller ◽

X Cao ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Near Infrared ◽

Assessment Tool ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Prognostic Assessment ◽

Infrared Spectral ◽

Spectral Tomography

Download Full-text

Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival

Journal of Surgical Oncology ◽

10.1002/jso.26216 ◽

2020 ◽

Vol 122 (8) ◽

pp. 1761-1769

Author(s):

Thomas L. Sutton ◽

Alexander Schlitt ◽

Stuart K. Gardiner ◽

Nathalie Johnson ◽

Jennifer R. Garreau

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Residual Cancer ◽

Cancer Burden ◽

Residual Cancer Burden ◽

Time To Surgery

Download Full-text